Advertisement
IDYA vs OVID
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Buy and OVID is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IDYA’s FA Score shows that 0 FA rating(s) are green whileOVID’s FA Score has 1 green FA rating(s).
- IDYA’s FA Score: 0 green, 5 red.
- OVID’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IDYA’s TA Score shows that 5 TA indicator(s) are bullish while OVID’s TA Score has 4 bullish TA indicator(s).
- IDYA’s TA Score: 5 bullish, 4 bearish.
- OVID’s TA Score: 4 bullish, 5 bearish.
Price Growth
IDYA (@Biotechnology) experienced а +1.97% price change this week, while OVID (@Biotechnology) price change was +15.92% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +3.59%. For the same industry, the average monthly price growth was +34.25%, and the average quarterly price growth was +14.95%.
Reported Earning Dates
IDYA is expected to report earnings on Aug 12, 2025.
OVID is expected to report earnings on Aug 18, 2025.
Industries' Descriptions
@Biotechnology (+3.59% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| IDYA | OVID | IDYA / OVID | |
| Capitalization | 1.95B | 24.4M | 8,000% |
| EBITDA | -356.46M | -56.4M | 632% |
| Gain YTD | -13.268 | -63.264 | 21% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 7M | 548K | 1,277% |
| Total Cash | 693M | 43M | 1,612% |
| Total Debt | 26M | 14.4M | 181% |
IDYA | OVID | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 75 | 19 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 63 Fair valued | 29 Undervalued | |
PROFIT vs RISK RATING 1..100 | 69 | 100 | |
SMR RATING 1..100 | 94 | 97 | |
PRICE GROWTH RATING 1..100 | 48 | 65 | |
P/E GROWTH RATING 1..100 | 100 | 94 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
OVID's Valuation (29) in the Pharmaceuticals Major industry is somewhat better than the same rating for IDYA (63) in the null industry. This means that OVID’s stock grew somewhat faster than IDYA’s over the last 12 months.
IDYA's Profit vs Risk Rating (69) in the null industry is in the same range as OVID (100) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to OVID’s over the last 12 months.
IDYA's SMR Rating (94) in the null industry is in the same range as OVID (97) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to OVID’s over the last 12 months.
IDYA's Price Growth Rating (48) in the null industry is in the same range as OVID (65) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to OVID’s over the last 12 months.
OVID's P/E Growth Rating (94) in the Pharmaceuticals Major industry is in the same range as IDYA (100) in the null industry. This means that OVID’s stock grew similarly to IDYA’s over the last 12 months.
| IDYA | OVID | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 69% | N/A |
| Stochastic ODDS (%) | 1 day ago 73% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 70% | 1 day ago 77% |
| MACD ODDS (%) | 1 day ago 71% | 1 day ago 77% |
| TrendWeek ODDS (%) | 1 day ago 77% | 1 day ago 78% |
| TrendMonth ODDS (%) | 1 day ago 81% | 1 day ago 77% |
| Advances ODDS (%) | 1 day ago 76% | 1 day ago 73% |
| Declines ODDS (%) | 4 days ago 77% | 14 days ago 88% |
| BollingerBands ODDS (%) | 1 day ago 77% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 81% | 1 day ago 90% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| SMCFX | 74.11 | 0.95 | +1.30% |
| American Funds SMALLCAP World F2 | |||
| VGISX | 34.71 | N/A | N/A |
| Virtus Duff & Phelps Glb Rl Estt Secs I | |||
| GCMTX | 34.62 | N/A | N/A |
| Goldman Sachs Mid Cap Value Inv | |||
| GIDWX | 17.35 | N/A | N/A |
| Goldman Sachs US Eq Div and Premium R6 | |||
| HLIDX | 14.55 | N/A | N/A |
| Harding Loevner Intl Dev Mkts Eq Inst | |||
IDYA and
Correlation & Price change
A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.
| Ticker / NAME | Correlation To IDYA | 1D Price Change % | ||
|---|---|---|---|---|
| IDYA | 100% | +1.27% | ||
| IMNM - IDYA | 60% Loosely correlated | +1.27% | ||
| CGON - IDYA | 60% Loosely correlated | +0.04% | ||
| XENE - IDYA | 56% Loosely correlated | +1.39% | ||
| CRNX - IDYA | 56% Loosely correlated | -1.38% | ||
| COGT - IDYA | 55% Loosely correlated | +3.68% | ||
More | ||||
OVID and
Correlation & Price change
A.I.dvisor indicates that over the last year, OVID has been closely correlated with JBIO. These tickers have moved in lockstep 79% of the time. This A.I.-generated data suggests there is a high statistical probability that if OVID jumps, then JBIO could also see price increases.
| Ticker / NAME | Correlation To OVID | 1D Price Change % | ||
|---|---|---|---|---|
| OVID | 100% | +9.06% | ||
| JBIO - OVID | 79% Closely correlated | -11.99% | ||
| ATXS - OVID | 46% Loosely correlated | -3.72% | ||
| BEAM - OVID | 46% Loosely correlated | +2.27% | ||
| IDYA - OVID | 44% Loosely correlated | +1.27% | ||
| SYRE - OVID | 43% Loosely correlated | +3.96% | ||
More | ||||